Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.

MLA

Bordron, Anne, et al. “Resistance to Complement Activation, Cell Membrane Hypersialylation and Relapses in Chronic Lymphocytic Leukemia Patients Treated with Rituximab and Chemotherapy.” Oncotarget, vol. 9, no. 60, Aug. 2018, pp. 31590–605. EBSCOhost, https://doi.org/10.18632/oncotarget.25657.

APA

Bordron, A., Bagacean, C., Mohr, A., Tempescul, A., Bendaoud, B., Deshayes, S., Dalbies, F., Buors, C., Saad, H., Berthou, C., Pers, J.-O., & Renaudineau, Y. (2018). Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. Oncotarget, 9(60), 31590–31605. https://doi.org/10.18632/oncotarget.25657

Chicago

Bordron, Anne, Cristina Bagacean, Audrey Mohr, Adrian Tempescul, Boutahar Bendaoud, Stéphanie Deshayes, Florence Dalbies, et al. 2018. “Resistance to Complement Activation, Cell Membrane Hypersialylation and Relapses in Chronic Lymphocytic Leukemia Patients Treated with Rituximab and Chemotherapy.” Oncotarget 9 (60): 31590–605. doi:10.18632/oncotarget.25657.